Highlights from the first ITM2B Symposium
Mutations in the gene integral membrane protein 2B (ITM2B; also known as BRI2) cause rare, autosomal dominant inherited forms of dementia and retinal dystrophy. The first family with ITM2B-linked dementia was described in 1933 and the genetic cause of disease was discovered in 1999, namely disruption of a stop codon causing an extended peptide. However, a detailed understanding of the pathomechanisms of disease remains limited. ITM2B-linked dementia research has witnessed major advancements in the previous 5 years, including the description of three new families and an appreciation of microglial-enriched expression of ITM2B. Additionally, in spite of distinct amyloid pathology (composed of extended ITM2B peptide fragments), ITM2B-linked dementias exhibit identical pathological tau folding when compared with Alzheimer’s disease. For these reasons, the first ITM2B-focused scientific symposium was held, bringing together researchers and establishing a network to support progress. Here we report the highlights of the symposium. The group agreed upon the establishment of an ITM2B consortium for the sharing of resources, addressing the rarity of the diseases. An umbrella term “ITM2B-linked neurodegeneration” was agreed upon, to refer to the group of diseases that includes familial British, Danish, Chinese, and Korean dementias, ITM2B-associated ataxia, and retinal dystrophy. This successful first meeting has spurred discussions into a second symposium in 2027. The group aim for continued collaboration and future joint funding applications to drive progress in ITM2B-linked research.
Authors
- Tamás Révész (ORCID: https://orcid.org/0000-0003-2501-0259)
- Anllely Fernández (ORCID: https://orcid.org/0000-0001-7070-1425)
- John Hardy (ORCID: https://orcid.org/0000-0002-3122-0423)
- Juliette Wohlschlegel (ORCID: https://orcid.org/0000-0003-4317-9066)
- Cristian A. Lasagna‐Reeves (ORCID: https://orcid.org/0000-0002-5499-3082)
- Gordon Terence Plant (ORCID: https://orcid.org/0000-0002-9285-071X)
- Argyro Alatza (ORCID: https://orcid.org/0000-0002-3342-6804)
- Eleanor Wheeler (ORCID: https://orcid.org/0000-0002-8616-6444)
- Selina Wray (ORCID: https://orcid.org/0000-0003-3062-7050)
- Tammaryn Lashley (ORCID: https://orcid.org/0000-0001-7389-0348)
- Alexandra Moreno-García (ORCID: https://orcid.org/0000-0003-2971-7374)
- Rubén Vidal (ORCID: https://orcid.org/0000-0002-5803-3871)
- Charles Arber (ORCID: https://orcid.org/0000-0002-9743-8134)
- Lucrezia Bruno (ORCID: https://orcid.org/0000-0002-6921-0060)
- Henry Houlden (ORCID: https://orcid.org/0000-0002-2866-7777)
- Simon Mead (ORCID: https://orcid.org/0000-0002-4326-1468)
- Katie Thompson
- Ko Woon Kim
- Samuel Crawford
Institutions
- Baylor College of Medicine (US)
- University of Washington (US)
- Jeonbuk National University Hospital (KR)
- MRC Prion Unit (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- Indiana University School of Medicine (US)
- UCL Queen Square Institute of Neurology (GB)
- University College London (GB)
- Indiana University – Purdue University Indianapolis (US)
- Indiana University (US)
- Jeonbuk National University (KR)
Publication Details
- Journal
- Brain Communications
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1093/braincomms/fcag449
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- BrightFocus Foundation
- Alzheimer's Society
- National Institute for Health and Care Research
- University College London
- Fondation de France